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Abstract
Background: Statistical tests of heterogeneity are very popular in meta-analyses, as heterogeneity might indicate 
subgroup effects. Lack of demonstrable statistical heterogeneity, however, might obscure clinical heterogeneity, 
meaning clinically relevant subgroup effects.
Methods: A qualitative, visual method to explore the potential for subgroup effects was provided by a modification of 
the forest plot, i.e., adding a vertical axis indicating the proportion of a subgroup variable in the individual trials. Such a 
plot was used to assess the potential for clinically relevant subgroup effects and was illustrated by a clinical example on 
the effects of antibiotics in children with acute otitis media.
Results: Statistical tests did not indicate heterogeneity in the meta-analysis on the effects of amoxicillin on acute otitis 
media (Q = 3.29, p = 0.51; I2 = 0%; T2 = 0). Nevertheless, in a modified forest plot, in which the individual trials were 
ordered by the proportion of children with bilateral otitis, a clear relation between bilaterality and treatment effects 
was observed (which was also found in an individual patient data meta-analysis of the included trials: p-value for 
interaction 0.021).
Conclusions: A modification of the forest plot, by including an additional (vertical) axis indicating the proportion of a 
certain subgroup variable, is a qualitative, visual, and easy-to-interpret method to explore potential subgroup effects in 
studies included in meta-analyses.
Background
Practice guidelines increasingly rely on systematic
reviews and meta-analyses. The ultimate purpose of a
meta-analysis is to produce an overall estimate of the
effect of an intervention by quantitatively combining
study results. However, several issues arise in the process
of integrating evidence. One of the main issues concerns
heterogeneity, i.e. the extent to which different studies
give similar or different results. Statistical tests are rou-
tinely available to evaluate the presence of statistical het-
erogeneity (between-study heterogeneity) in meta-
analysis [1-3]. Strictly speaking, however, one is not really
interested in statistical heterogeneity. What one is inter-
ested in is clinical heterogeneity, i.e., specific causes that
underlie heterogeneity across studies, especially since the
direction and magnitude of the effect in the meta-analysis
is often used to guide decisions about clinical practice for
a wide range of patients. Yet, relevant subgroup effects
may not be revealed by a test for (statistical) heterogene-
ity. In meta-regression analysis the relation between a
certain subgroup characteristic and the size of the treat-
ment effect can in fact be quantified, but such analyses
might be difficult to conduct or interpret, and rely on sev-
eral assumptions. Furthermore, the observed treatment
effect and subgroup variables are actually estimates,
rather than true values. Ordinary meta-regression analy-
sis (weighted least squares) does not take measurement
errors in treatment and subgroup variables adequately
into account and may consequently give a biased estimate
of the slope of the regression line [4]. We will show that
clinically relevant subgroup effects can be explored in a
simple manner by modifying the forest plot.
Methods
Tests for heterogeneity
Several tests have been developed to assess heterogeneity.
The so-called Cochrane's Q (or Cochrane's χ2 test)
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Page 2 of 5weights the observed variation in treatment effects by the
inverse of the variation in each study [5]. A large value of
Q indicates large differences between studies, and hence,
the effects from the included studies can be considered
heterogeneous [2]. A modification of Cochrane's Q is the
measure I2, which is the ratio of variation that exceeds
chance variation and the total variation in the treatment
effects. Possible values for I2 range from zero to one, with
a high value for I2 indicating much heterogeneity. Both Q
and I2 are standardized measures, meaning that they
don't depend on the metric of the effect size. A third mea-
sure of heterogeneity, indicating the variance of the true
effect sizes is T2, where (similar to Q and I2) large values
of T2 indicate heterogeneity. This method of estimating
the variance between studies (T2) is also known as the
method of moments, or the DerSimonian and Laird
method [6]. A fourth measure is the prediction interval,
which indicates the distribution of true effect sizes and is
based on T2 [2]. Cochrane's Q is sensitive to the number
of studies and especially when the number of studies
included in a meta-analysis is small, Cochrane's Q too
often leads to false-positive conclusions (too large type I
error) [7]. The modification I2 takes account of the num-
ber of included studies and has a correct probability of a
type I error [3]. The measure T2 is insensitive to the num-
ber of studies as well, but sensitive to the metric of the
effect size [2].
Currently, I2 appears to be used routinely in most pub-
lished meta-analyses. Interestingly, the observed amount
of heterogeneity depends on the effect measure that is
considered in a meta-analysis: little heterogeneity when
considering odds ratios implies large heterogeneity when
considering risk differences and vice versa [8]. The reason
for this is analogous to effect measure modification in a
single study: if odds ratios are the same between strata
(e.g., age categories) of a single study, risk differences are
likely to differ between strata.
Consequences of heterogeneity
Tests for heterogeneity indicate whether the variation in
observed effects is either large or small. When heteroge-
neity is low (non-significant) for the chosen effect mea-
sure, variation between effects from different studies is
(relatively) small. Thus, a fixed effects model can be used
to synthesize the data, since the assumption underlying a
fixed effects model is that the treatment effect is the same
in each study, and variation between studies is due to
sampling (i.e., chance) [3,7]. If variation in the effects
found in the different studies is (relatively) large they
could be considered as sampled from a distribution of
effects, i.e., the true treatment effect that is estimated in
the different studies is not a single value, but rather a dis-
tribution of effects. In that case, a random effects model
has been recommended [3,7]. It has also been suggested
that heterogeneity is inevitable in meta-analysis [9], and
random effects models are therefore obligatory. If, how-
ever, heterogeneity is (very) large, one could even con-
sider not pooling results from different studies at all,
since studies are likely to be (very) different [2]. Further-
more, if there is a cause for heterogeneity, for example a
subgroup effect, neither fixed nor random effects models
take such relations between the effect size and subgroups
into account. Another explanation for heterogeneity
(other than differential treatment effects) could be a sys-
tematic error in the included studies. For example, sys-
tematic error that is related to e.g., the proportion of
women, or differences in methodology (e.g., differences
in outcome ascertainment) of the included studies [10].
Relevant subgroup effects
Test for heterogeneity do not indicate possible causes for
heterogeneity. In fact, testing for heterogeneity in two
meta-analyses - one with a clear cause for heterogeneity
(e.g., a subgroup effect), and the other not - can lead to
the same conclusions with respect to heterogeneity. For
example, consider a hypothetical meta-analysis of five
randomized trials on the effects of some treatment. Each
trial consisted of 200 subjects, randomized to either
treatment or placebo and the baseline risk for the out-
come was 50%. The effects and their 95% confidence
intervals are shown in Figure 1. Testing for heterogeneity
indicated that these effects could not be considered het-
erogeneous (Q = 3.2, p = 0.52; I2 = 0%; T2 = 0). A closer
Figure 1 Forest plot of a hypothetical meta-analysis of five stud-
ies. The treatment effects and corresponding 95% confidence intervals 
of five studies included in a hypothetical meta-analysis are shown. The 
dashed line (- - - -) indicates no treatment effect. The studies are or-
dered chronologically.
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of women included in the studies differed considerably:
from 0% to 100%. Rearranging the order of the effects by
the proportion of women included in each study resulted
in Figure 2. The tests for heterogeneity reached exactly
the same conclusions, since the ordering of the observed
treatment effects is not taken into account when testing
for heterogeneity. Clearly, in the modified forest plot (Fig-
ure 2) the data have a certain pattern, which may indicate
a differential treatment effect among men and women,
i.e., modification of the treatment effect by sex. In fact,
the treatment was effective in women (RR = 0.7), but not
in men (RR = 1.0), and when analyzing the individual
patient data (i.e., fitting a regression model to the individ-
ual patient data rather than the aggregated data and
including a factor to account for differences between tri-
als), a statistically significant subgroup effect was indeed
found (p-value for interaction 0.011). Hence, in aggre-
gated data the differential treatment effect by sex was not
indicated by tests for heterogeneity, but only suggested by
the modified forest plot, whereas in individual patient
data this differential effect was clearly observed and sta-
tistically significant. Whether this subgroup effect is clin-
ically relevant is rather subjective, but we can conclude
that tests for heterogeneity on aggregated data appear not
to tell the whole story about heterogeneity on individual
patient data.
What is important is that a regular forest plot (Figure 1)
only contains a horizontal axis (indicating the effect size),
whereas the modified forest plot (Figure 2) contains two
axes. Both in the regular forest plot and in the modified
forest plot the horizontal axis indicates the effect size.
The additional vertical axis in the modified forest plot
indicates the proportion of a certain subgroup variable in
the included studies. Importantly, the vertical axis does
not simply indicate the order of the subgrouping variable,
but also scales this variable.
An often used quantitative approach to investigate the
association between a certain subgroup characteristic
and the size of the treatment effect is by applying meta-
regression analysis [11]. Such analyses however rely on
several assumptions, e.g., linearity of the association, and
might be hard to interpret for their quantitative nature.
Furthermore, in ordinary meta-regression analysis the
treatment effects from the included studies are handled
as if they are true values rather than estimates, which can
result in bias when using least squares regression [4]. In
addition, aggregated data meta-(regression) analyses are
inappropriate to estimate unbiased treatment effects in
patient subgroups, since such comparisons are observa-
tional by nature. As a result, the observed subgroup effect
may be attributable to other variables than the subgroup-
ing variable [12]. Furthermore, as indicated before, nei-
ther fixed nor random effects models address the cause
for heterogeneity. Individual patient data meta-analysis
can be a valid alternative to study subgroup effects [12].
In conclusion, the modified forest plot is a qualitative,
visual alternative to assess the potential for a clinical rele-
vant subgroup effects.
Results
In empirical meta-analyses subgroup effects can lead to
patterns in a modified forest plot as well, as is illustrated
by the following clinical example. In an individual patient
data (IPD) meta-analysis on the effects of amoxicillin in
children with acute otitis media, amoxicillin was more
effective in children with bilateral otitis (p-value for inter-
action 0.021) [13]. Prior to this IPD meta-analysis age was
thought to modify the effects of amoxicillin. Most of the
studies included in the meta-analysis explicitly men-
tioned age distributions, but did not report the propor-
tion of bilateral otitis. If the included studies, however,
had reported the proportion of bilateral otitis, indications
for the differential treatment effect found in the IPD
meta-analysis could already have been suggested in a
meta-analysis on the aggregated data (i.e., by construct-
ing a modified forest plot). In Figure 3, the studies are
chronologically ordered, whereas in Figure 4 their order
is based on the proportion of children with bilateral acute
Figure 2 Modified forest plot of a hypothetical meta-analysis of 
five studies, ordered by the proportion of women in each study. 
The treatment effects and corresponding 95% confidence intervals of 
five studies included in a hypothetical meta-analysis are shown. The 
dashed line (- - - -) indicates no treatment effect. The studies are or-
dered by the proportion of women that was included in each study. 
The studies differ on the proportion of included women (0%, 25%, 50%, 
75%, and 100%). The hypothetical treatment is effective in women (RR 
= 0.7), but not in men (RR = 1.0).
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tioned example on the hypothetical meta-analysis, the
measures of heterogeneity are the same for the Figures 3
and 4, as the order of the effects is not taken into account
(Q = 3.29, p = 0.51; I2 = 0%; T2 = 0). What is striking,
though, is the apparent relation between the proportion
of bilaterality and the effects of amoxicillin in the differ-
ent trials. Hence, based on the modified forest plot (Fig-
ure 4) a differential treatment effect for children with and
without bilateral otitis is suggested. Similar to the hypo-
thetical data presented above, in this clinical example
tests for heterogeneity on aggregated data did not concur
with the test for heterogeneity on individual patient data.
Discussion and conclusions
Neither the absence nor the presence of heterogeneity (as
indicated by the result of heterogeneity tests) in aggre-
gated data meta-analyses appears to be indicative for sub-
group effects. Irrespective of statistical test results,
subgroup effects can be present in the data. A modified
forest plot, including an additional (vertical) axis indicat-
ing the proportion of the subgroup variable (e.g., the pro-
portion of bilateral otitis), may be helpful to identify
clinically relevant subgroup effects. Unfortunately, pat-
terns in a modified forest plot can only indicate (qualita-
tive) subgroup effects. To quantify a subgroup effect,
meta-regression analysis can be applied, but validity of
results is then subject to several assumptions, and indi-
vidual patient data meta-analysis might be needed [12].
The modified forest plot is a qualitative, visual, and easy-
to-interpret alternative for exploring potential clinically
relevant subgroup effects in studies included in aggre-
gated data meta-analyses and should be considered when
exploring such effects.
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Figure 3 Forest plot of a meta-analysis on five studies on the ef-
fects of amoxicillin in children with acute otitis media. The treat-
ment effects and corresponding 95% confidence intervals of five out of 
six randomized trials included in an IPD meta-analysis on the effects of 
amoxicillin in children with acute otitis media are shown [13]. The 
dashed line (- - - -) indicates no treatment effect. The studies are or-
dered chronologically. In the excluded study, bilaterality was not regis-
tered.
Figure 4 Modified forest plot of a meta-analysis on five studies 
on the effects of amoxicillin in children with acute otitis media, 
ordered by the proportion of bilateral otitis in each study. The 
treatment effects and corresponding 95% confidence intervals of five 
out of six randomized trials included in an IPD meta-analysis on the ef-
fects of amoxicillin in children with acute otitis media are shown [13]. 
The dashed line (- - - -) indicates no treatment effect. The studies are or-
dered by the proportion of children with bilateral otitis. In the excluded 
study, bilaterality was not registered.
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